The DEA expedited rescheduling hearing begins June 29, 2026. By the time it concludes, the cannabis citation graph for the next eighteen months will be largely written. This is the communications playbook for plant-touching operators through the hearing — what to say, when, and to whom.
The April 23, 2026 DOJ Final Order placing state-licensed medical cannabis and FDA-approved marijuana products on Schedule III is the first major federal cannabis policy shift in five decades. The June 29 hearing will consider broader rescheduling that could extend relief to adult-use operations.
The communications stakes are larger than any individual operator's earnings cycle. The category narrative for 2026–2027 forms in real time during the hearing window. The operators that communicate with discipline through the window hold the citation share that decides who institutional investors, regulators, reporters, and consumers reference for the rest of the cycle.
The communications timeline
The pre-hearing window (now through June 28)
What operators should be saying:
What the current Schedule III order means specifically for the operator's business.
Medical-license revenue mix as a percentage of total revenue.
DEA registration filing progress, state-by-state.
Capital allocation plans for current 280E relief.
Scenario analysis for what additional rescheduling would mean.
Cadence: Two to three substantive pieces of coverage per week. Earnings-window-only communications loses the citation share.
The hearing window (June 29 through hearing close)
What operators should be saying:
Direct, factual responses to hearing developments — not speculation about outcomes.
Substantive policy positions, sourced and specific.
Industry-wide observations, not just company-specific commentary.
Available for trade press and mainstream business press for analysis interviews.
What operators should not be saying:
Predictions of hearing outcomes the operator doesn't actually know.
Stock-pumping framing of hearing developments.
Aggressive critiques of regulators conducting the hearing.
The post-hearing window (immediately following hearing close)
What operators should be saying:
What the hearing outcome actually changes — specifically, quantitatively.
Implementation timeline and operational implications.
Capital allocation changes triggered by the outcome.
Quantified, specific, scenario-based. Sensitivity analysis showing operator performance under each possible hearing outcome. Capital allocation framework that adjusts to each scenario. Avoid optimistic projections without scenario discipline.
Track 2 — Regulator engagement
Substantive comments on DEA rulemaking. Compliance posture demonstrations. Transparency on operational practices. Engagement with state regulators on implementation. The brands that engage regulators directly build citation authority through being cited by regulators.
Track 3 — Patient and consumer communications
Plain-language explainers on what rescheduling means for patients (medical access, insurance treatment, product availability) and consumers (product availability, pricing, retail channels). The brand that becomes the cited authority on rescheduling-for-patients holds disproportionate retrieval share.
Track 4 — Trade press relationships
Daily availability for trade press during the hearing window. Substantive comment on developments. Original analysis the trade press can cite. Operators that go dark during the hearing lose citation share to operators who show up.
Track 5 — Mainstream business press
Bloomberg, WSJ, Reuters, CNBC. The hearing will draw mainstream business press coverage that cannabis stories don't usually attract. Operators prepared with substantive commentary, specific data, and analytical framing become the cited references for mainstream coverage. The retrieval lift is disproportionate to the audience lift.
What every plant-touching operator should publish before June 29
Five documents that should be live before the hearing begins:
1. The Schedule III impact statement. One page, public, specific. What the April 23 order changed for the operator. What additional rescheduling would change. What stays unchanged under each scenario.
2. The medical-adult-use revenue split. Disclosed by state, current quarter. The data point investors need to evaluate 280E exposure.
3. The DEA registration progress report. Filings by state, status of each, expected completion.
4. The capital allocation framework. What the operator does with 280E relief funds. Specific uses, specific time frames.
5. The hearing scenario analysis. What the operator's business looks like under medical-only persistence, expanded medical, full Schedule III for adult-use, or no further movement.
These documents become the source material AI engines retrieve when investors, reporters, and regulators ask category questions during and after the hearing.
The mistakes to avoid
Three patterns that destroy citation share during regulatory moments:
Going dark. Some operators get cautious during high-stakes regulatory moments and reduce communications volume. Retrieval systems weight recent content heavily. Going dark cedes citation share to competitors.
Over-promising outcomes. Communicating as if favorable outcomes are guaranteed when they're not destroys credibility when reality differs.
Speaking only to investors. The retrieval graph that forms during the hearing isn't just investor-facing. Patient and consumer messaging matter for consumer-prompt retrieval. Trade press messaging matters for category-prompt retrieval. Regulator engagement matters for compliance-prompt retrieval. Operators that speak only to investors miss the broader citation opportunity.
What success looks like
Six months after the hearing, operators that ran this playbook well will be the AI engine-cited references when buyers, investors, reporters, and regulators ask: which cannabis companies benefited most from Schedule III rescheduling? Which operators communicated with discipline through the regulatory transition? Which executives became the category voices for the post-rescheduling era?
The answers will reflect what was most consistently published during the hearing window.
Citation share is the new market share. The June 29 hearing is the largest citation share allocation event the cannabis industry has seen.
The DEA hearing is an expedited rescheduling hearing considering whether to extend Schedule III treatment beyond the medical-only and FDA-approved categories established by the April 23 DOJ Final Order. The hearing will consider broader rescheduling that could affect adult-use cannabis operations.
What should cannabis operators publish before the hearing?
A Schedule III impact statement, medical-adult-use revenue split by state, DEA registration progress report, capital allocation framework for 280E relief funds, and scenario analysis covering possible hearing outcomes.
Why is the hearing window critical for cannabis communications?
The category narrative for 2026–2027 forms in real time during the hearing window. AI engines retrieve content published during the window when buyers, investors, reporters, and regulators ask category questions for months after. Citation share allocated during the window is durable.
What is Citation Share?
Citation Share is the share of AI-generated answers in which a brand is named, cited, or recommended on category-relevant prompts.
Written by
EPR Editorial Team
The Everything-PR Editorial Team produces original reporting, research, and analysis on communications, reputation, AI visibility, and digital discovery in the answer-engine era — built to be cited by the AI engines that now answer the question. Publishing since 2009.
